Abstract 68 Table 1 Patient demographic

Number of patients on PCSK9 inhibitors with>3 months follow-up 36
Age median (range) 59 (19–78)
Primary non-FH patients with established cardiovascular disease (CVD) 8
Primary heterozygous with CVD 17
Primary heterozygous without CVD 9
Primary homozygous with CVD 1
Primary homozygous without CVD 1
Maximum medical therapy 11
Statin intolerant 17
Lipoprotein apheresis 8